Results 111 to 120 of about 575,729 (357)

Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. [PDF]

, 2014
PurposeWe hypothesized that bortezomib, an agent that suppresses HIF-1α transcriptional activity, when combined with bevacizumab, would obviate the HIF-1α resistance pathway.
Amin, Hesham M, Angelo, Laura S, Falchook, Gerald S, Hess, Kenneth, Hong, David, Howard, Adrienne N, Huang, Mei, Jackson, Edward F, Janku, Filip, Kurzrock, Razelle, Lawhorn, Kristie N, Naing, Aung, Ng, Chaan S, Parkhurst, Kristin L, Tannir, Nizar M, Vishwamitra, Deeksha, Wheler, Jennifer J   +16 more
core   +2 more sources

Single‐Cell Transcriptome Atlas Reveals the Underlying Mechanism of Kynurenic Acid in the Regulation of Tumor Immune Microenvironment in Glioblastoma

Advanced Science, EarlyView.
KYNA regulates the tumor immune microenvironment in glioblastoma. KYNA reprograms the balance between T cell exhaustion and activation to suppress glioblastoma progression through inhibiting exhaustion‐associated markers (such as PD‐1, LAG3, and TOX) and enhancing immune activation and cytotoxicity markers including granzymes GZMA and GZMB.
Di Chen, Liming Sun, Jiajun Chen, Zi Ye, Xuqiang Zhu, Hongjiang Li, Lixin Wu, Guohua Zhao, Qinghao Zhang, Guangyi Jiang, Yuchen Ji, Yake Xue, Hongwei Li, Ruokun Chen, Hongwei Zheng, Rong Zeng, Dongming Yan, Yong Zhang, Xueyuan Li, Jing Yan   +19 more
wiley   +1 more source

Identification of PANoptosis-related signature reveals immune infiltration characteristics and immunotherapy responses for renal cell carcinoma

BMC Cancer
PANoptosis is a specific type of inflammatory programmed cell death (PCD) modality that can be involved in three key modes of cellular programmed cell death-pyroptosis, apoptosis and necroptosis. We analyzed PANoptosis activity in three common renal cell
Yan Xu, Jingqi Hua, Hongliang Que, Tengyue Zeng, Quan Li, Junpeng Deng, Jianjun Xie   +6 more
doaj   +1 more source

Localized abdominal wall metastasis of papillary renal cell carcinoma: a case report

Frontiers in Surgery
IntroductionPapillary renal cell carcinoma accounts for one tenth of all renal cell carcinomas. Compared to other renal cell carcinoma subtypes, it is more often localized at the time of diagnosis and rarely metastasizes to the skin.
Chadi Nahal, Claire Wunker, Jennifer Keller   +2 more
doaj   +1 more source

Gene amplification and overexpression of HER2 in renal cell carcinoma [PDF]

, 2002
Objective To determine the frequency of HER2 genetic abnormalities in renal cell carcinoma (RCC) and hence assess the potential suitability of Herceptin(TM) immunotherapy.
Aitchison, M., Bartlett, J.M.S., Latif, Z., Underwood, M.A., Watters, A.D.   +4 more
core   +2 more sources

Regulating Tumor Metabolic Reprogramming with Biomimetic Co‐Delivery of Simvastatin and Kynureninase for Immunotherapy

Advanced Science, EarlyView.
After the intravenous injection of biomimetic and pH/ROS‐responsive PTSK@CRM, the nanoparticles can be accumulated in tumors and release Sim and KYNase to inhibit the tumor growth, regulate the metabolism of cholesterol and Kyn, and reverse the immunosuppressive tumor microenvironment.
Jiaxin Yin, Shengcai Yang, Zengguang Liu, Songchen Zhao, Siyu Sun, Ziling Liu, Quanshun Li   +6 more
wiley   +1 more source

Nutritional screening is strongly associated with overall survival in patients treated with targeted agents for metastatic renal cell carcinoma [PDF]

, 2015
Weijie Gu, Guiming Zhang, Lijiang Sun, Qi Ma, Yue Cheng, Hailiang Zhang, Guohai Shi, Yao Zhu, Dingwei Ye   +8 more
openalex   +1 more source

Three‐Year Follow‐Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer‐Associated Fibroblast Heterogeneity Corresponding to PD‐1 Blockade Efficacy

Advanced Science, EarlyView.
Heterogeneous cancer‐associated fibroblasts orchestrate dual immune microenvironments in LAGC. Abstract The potential for immunotherapy in patients with locally advanced gastric cancer (LAGC) is recently confirmed. To report the 3‐year follow‐up data are aimed from a novel clinical trial. This is a prospective single‐arm phase II trial.
Yao Lin, Xiong Sun, Chengguo Li, Ming Yang, Ke Wu, Ke Liu, Anshu Li, Xiaoming Shuai, Kailin Cai, Zheng Wang, Guobin Wang, Peng Zhang, Jianfeng Shen, Kaixiong Tao, Yuping Yin   +14 more
wiley   +1 more source

Long-term response to nivolumab and acute renal failure in a patient with metastatic papillary renal-cell carcinoma and a PD-L1 tumor expression increased with sunitinib therapy: A case report.

Frontiers in Oncology, 2016
Introduction: Papillary renal-cell carcinoma, which represents around 20% of renal cell carcinomas, is a heterogeneous disease that includes different tumor types with several clinical and molecular phenotypes.
Juan Ruiz-Bañobre, Urbano Anido, Ihab Abdulkader, José Antúnez-López, Rafael López-López, Jorge García-González   +5 more
doaj   +1 more source

Surgical excision of renal cell carcinoma with caval and intra-atrial tumour thrombus extension using deep hypothermic circulatory arrest [PDF]

, 2013
Surgery for tumour thrombus extension in Renal Cell Carcinoma may be associated with a good prognosis if no distant metastases are identified and if the thrombus can be completely excised.
Bugeja, Simon, Galea, Joseph, German, Karl, Zammit, Patrick   +3 more
core